Damora Therapeutics, Inc. (DMRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US36322Q2066
Damora Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -210.87 m USD |
| EBIT | -209.79 m USD |
| Net income | -209.84 m USD |
| Diluted EPS – continuing operations | 3.98 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
More stocks
- TRIMAS CORP (TRS)
- Shanxi Lanhua Sci-Tech Venture Co Ltd (600123.SS)
- Topoint Technology Co Ltd (8021.TW)
- Shanghai OPM Biosciences Co. Ltd. A (688293.SS)
- NEXTNAV INC. (NN)
- 3R Petroleum Oleo E Gas SA Ordinary Shares (BRAV3.SA)
- China Modern Dairy Holdings Ltd (1117.HK)
- Inmyshow Digital Technology Group Co Ltd (600556.SS)
- Hyundai Department (069960.KS)
- FIRST MID BANCSHARES, INC. (FMBH)
- Turning Point Brands, Inc. (TPB)
- INNODATA INC (INOD)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.